drugset / Trial / NCT07421037

Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older

NCT07421037

Phase 1 Active not recruiting 80 enrolled Ab&B Bio-tech Co., Ltd.JS Yither Biotech Co., Ltd · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The objective of this study was to evaluate the safety of quadrivalent subunit influenza vaccine (adjuvant) in people aged 65 years and older.

Timeline

Start
2025-11-13
Primary completion
2026-12-13
Completion
2026-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent Subunit Influenza Vaccine (Adjuvant) Vaccine 0.25 ml Intramuscular
Subject Quadrivalent Subunit Influenza Vaccine (Adjuvant) Vaccine 0.5 ml Intramuscular
Background MF59 Other / unclassified 0.5 ml Intramuscular

Indications